Palvella Therapeutics, Inc. (PVLA) — Financial statements
Income statement, balance sheet, and cash flow for Palvella Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 26↓17.6% | 31 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 3↑17.4% | 2 | |
| Gross Profit | 0.00 | 0.00 | 0.00↓100.0% | 23↓20.4% | 29 | |
| Operating Expenses | ||||||
| R&D Expenses | 23↑180.2% | 8↓7.3% | 9↓82.5% | 50↓21.8% | 64 | |
| General & Administrative Expenses | 16↑165.2% | 6↑93.2% | 3 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 16↑165.2% | 6↑93.2% | 3↓81.2% | 16↓1.8% | 17 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 39↑173.9% | 14↑18.8% | 12↓82.2% | 67↓17.7% | 81 | |
| Total Costs & Expenses | 39↑173.9% | 14↑18.8% | 12↓82.9% | 69↓16.7% | 83 | |
| Operating Results | ||||||
| Operating Income | -39↓173.9% | -14↓18.8% | -12↑72.7% | -43↑16.1% | -52 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00↓100.0% | 3↑17.4% | 2 | |
| EBITDA | -36↓173.7% | -13↓170.2% | 19↑161.3% | -30↑29.7% | -43 | |
| EBIT | -36↓173.7% | -13↓170.2% | 19↑156.2% | -33↑27.2% | -46 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↑25.2% | -4↓168.9% | 6↑768.9% | 0.72↑17925.0% | 0.00 | |
| Interest Income | 3 | 0.00↓100.0% | 6↑768.9% | 0.72↑17925.0% | 0.00 | |
| Interest Expense | 6↑34.8% | 4 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -3↓176.6% | -0.98↑96.8% | -31↓199.7% | -10↓67.4% | -6 | |
| Other Income / Expenses | -3↑6.8% | -3↓110.9% | 31↑199.7% | 10↑67.4% | 6 | |
| Income Before Tax | -42↓139.3% | -17↓193.3% | 19↑156.2% | -33↑27.2% | -46 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -42↓139.3% | -17↓193.3% | 19↑156.2% | -33↑27.2% | -46 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -42↓139.3% | -17↓193.3% | 19↑156.2% | -33↑27.2% | -46 | |
| Bottom-Line Net Income | -42↓139.3% | -17↓197.3% | 18↑153.8% | -33↑27.2% | -46 | |
| EPS (Basic) | -3.71↑52.6% | -7.83↓153.1% | 14.74↑149.8% | -29.61↑47.8% | -56.69 | |
| EPS (Diluted) | -3.71↑52.6% | -7.83↓153.1% | 14.74↑149.8% | -29.61↑47.8% | -56.69 | |
| Weighted Average Shares | 11↑405.4% | 2↑75.6% | 1↑36.3% | 0.93↑15.3% | 0.81 | |
| Weighted Average Diluted Shares | 11↑405.4% | 2↑75.6% | 1↑36.3% | 0.93↑15.3% | 0.81 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.